218 related articles for article (PubMed ID: 10651689)
1. Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies.
Russell-Jones R
Br J Dermatol; 2000 Jan; 142(1):16-21. PubMed ID: 10651689
[TBL] [Abstract][Full Text] [Related]
2. The role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphomas.
Atta M; Papanicolaou N; Tsirigotis P
Transfus Apher Sci; 2012 Apr; 46(2):195-202. PubMed ID: 22067605
[TBL] [Abstract][Full Text] [Related]
3. Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature.
Quaglino P; Knobler R; Fierro MT; Savoia P; Marra E; Fava P; Bernengo MG
Int J Dermatol; 2013 Nov; 52(11):1308-18. PubMed ID: 23786842
[TBL] [Abstract][Full Text] [Related]
4. The treatment of cutaneous T-cell lymphoma with photopheresis.
Zic JA
Dermatol Ther; 2003; 16(4):337-46. PubMed ID: 14686977
[TBL] [Abstract][Full Text] [Related]
5. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma--the Düsseldorf and Munich experience.
Prinz B; Behrens W; Hölzle E; Plewig G
Arch Dermatol Res; 1995; 287(7):621-6. PubMed ID: 8534123
[TBL] [Abstract][Full Text] [Related]
6. Extracorporeal photopheresis in Sézary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone.
Fraser-Andrews E; Seed P; Whittaker S; Russell-Jones R
Arch Dermatol; 1998 Aug; 134(8):1001-5. PubMed ID: 9722731
[TBL] [Abstract][Full Text] [Related]
7. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
8. Extracorporeal photopheresis--a new approach for the treatment of cutaneous T cell lymphomas.
Gollnick HP; Owsianowski M; Ramaker J; Chun SC; Orfanos CE
Recent Results Cancer Res; 1995; 139():409-15. PubMed ID: 7597308
[TBL] [Abstract][Full Text] [Related]
9. Extracorporeal photopheresis: what is it and when should it be used?
Scarisbrick J
Clin Exp Dermatol; 2009 Oct; 34(7):757-60. PubMed ID: 19663836
[TBL] [Abstract][Full Text] [Related]
10. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
Geskin L
Skin Therapy Lett; 2007 Jun; 12(5):1-4. PubMed ID: 17609808
[TBL] [Abstract][Full Text] [Related]
11. Photopheresis in cutaneous T-cell lymphoma: five-year experience.
Crovetti G; Carabelli A; Berti E; Guizzardi M; Fossati S; De Filippo C; Bertani E
Int J Artif Organs; 2000 Jan; 23(1):55-62. PubMed ID: 12118838
[TBL] [Abstract][Full Text] [Related]
12. Extracorporeal photopheresis and multimodality therapy in patients with T-cell cutaneous lymphomas: Real-life experience in Argentina.
Baquero Rey JA; Zambrano Franco EA; Andrade Miranda A; Marciano S; Mazzuoccolo LD; Enz PA
J Clin Apher; 2021 Dec; 36(6):815-822. PubMed ID: 34478581
[TBL] [Abstract][Full Text] [Related]
13. 75% Complete Response and 15% Partial Response to Extracorporeal Photopheresis Combined With Other Therapies in Resistant Early Stage Cutaneous T-Cell Lymphoma.
Seremet S; Abhyankar S; Herd TJ; Aires D
J Drugs Dermatol; 2016 Oct; 15(10):1212-1216. PubMed ID: 27741338
[TBL] [Abstract][Full Text] [Related]
14. The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society.
Alfred A; Taylor PC; Dignan F; El-Ghariani K; Griffin J; Gennery AR; Bonney D; Das-Gupta E; Lawson S; Malladi RK; Douglas KW; Maher T; Guest J; Hartlett L; Fisher AJ; Child F; Scarisbrick JJ
Br J Haematol; 2017 Apr; 177(2):287-310. PubMed ID: 28220931
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group.
McKenna KE; Whittaker S; Rhodes LE; Taylor P; Lloyd J; Ibbotson S; Russell-Jones R; ;
Br J Dermatol; 2006 Jan; 154(1):7-20. PubMed ID: 16403088
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Extracorporeal Photopheresis for the Treatment of Patients With Erythrodermic (Stage T
Peacock A; Dehle F; Mesa Zapata OA; Prince HM; Gennari F; Taylor C
Value Health; 2022 Jun; 25(6):965-974. PubMed ID: 35667784
[TBL] [Abstract][Full Text] [Related]
17. Photopheresis in the treatment of cutaneous T-cell lymphoma: current status.
Zic JA
Curr Opin Oncol; 2012 Jan; 24 Suppl 1():S1-10. PubMed ID: 22157241
[TBL] [Abstract][Full Text] [Related]
18. Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience.
Siakantaris MP; Tsirigotis P; Stavroyianni N; Argyropoulos KV; Girkas K; Pappa V; Chondropoulos S; Papadavid E; Sakellari I; Anagnostopoulos A; Antoniou C; Dervenoulas J
Transfus Apher Sci; 2012 Apr; 46(2):189-93. PubMed ID: 22178592
[TBL] [Abstract][Full Text] [Related]
19. Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma.
Miller JD; Kirkland EB; Domingo DS; Scull H; Jekutis B; Dallas M; Cooper KD; Baron ED
Photodermatol Photoimmunol Photomed; 2007 Oct; 23(5):163-71. PubMed ID: 17803594
[TBL] [Abstract][Full Text] [Related]
20. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
